Granted Patent
B2
US 12,215,167 · App. 17/877,853 · Granted Feb 4, 2025
Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
Inventors:
Jan-Willem Theunissen (South San Francisco, CA); Andrew D. Avery (South San Francisco, CA); Allen G. Cai (South San Francisco, CA); Anthony Byron Cooper (South San Francisco, CA); Thi-Sau Migone (South San Francisco, CA)
Assignee:
ICONIC THERAPEUTICS LLC
C07K16/36A61K31/713A61K47/68031A61K47/6843A61K47/6849A61P27/02C12N5/10C12N15/63C07K2317/21C07K2317/24C07K2317/33C07K2317/34C07K2317/56C07K2317/565C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Provided herein are antibodies that specifically bind to human tissue factor (TF), anti-TF antibody-drug conjugates (ADCs), and compositions comprising the antibodies or ADCs. Also provided herein are methods of making and using the antibodies or ADCs, such as therapeutic and diagnostic methods.
Claims (22)
1. An antibody which binds to the extracellular domain of human Tissue Factor (TF), wherein the antibody comprises a VH-CDR1, a VH-CDR2, and a VH-CDR3 comprising the amino acid sequences of the VH-CDR1, the VH-CDR2, and the VH-CDR3, respectively, as set forth in a VH comprising the amino acid sequence of SEQ ID NO: 151, and a VL-CDR1, a VL-CDR2, and a VL-CDR3 comprising the amino acid sequences of the VL-CDR1, the VL-CDR2, and the VL-CDR3, respectively, as set forth in a VL comprising the amino acid sequence of SEQ ID NO: 152.
2. The antibody of claim 1 , wherein
(i) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO: 115, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO: 116, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO: 117, the VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 118, the VL-CDR2 comprises the amino acid sequence of SEQ ID NO: 119, and the VL-CDR3 comprises the amino acid sequence of SEQ ID NO: 120;
(ii) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO: 121, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO: 122, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO: 123, the VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 124, the VL-CDR2 comprises the amino acid sequence of SEQ ID NO: 125, and the VL-CDR3 comprises the amino acid sequence of SEQ ID NO: 126;
(iii) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO: 127, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO: 128, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO: 129, the VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 130, the VL-CDR2 comprises the amino acid sequence KAY, and the VL-CDR3 comprises the amino acid sequence of SEQ ID NO: 132;
(iv) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO: 133, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO: 134, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO: 135, the VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 136, the VL-CDR2 comprises the amino acid sequence of SEQ ID NO: 137, and the VL-CDR3 comprises the amino acid sequence of SEQ ID NO: 138;
(v) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO: 139, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO: 140, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO: 141, the VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 142, the VL-CDR2 comprises the amino acid sequence of SEQ ID NO: 143, and the VL-CDR3 comprises the amino acid sequence of SEQ ID NO: 144; or
(vi) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO: 145, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO: 146, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO: 147, the VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 148, the VL-CDR2 comprises the amino acid sequence KAY, and the VL-CDR3 comprises the amino acid sequence of SEQ ID NO: 150.
3. The antibody of claim 1 , wherein
the antibody comprises a VH sequence of SEQ ID NO:151 and a VL sequence of SEQ ID NO: 152.
4. A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable excipient.
5. A kit comprising
(i) the antibody of claim 1 ; and
(ii) instructions for use.
6. The antibody of claim 1 , wherein the VH-CDR1, the VH-CDR2, the VH-CDR3, the VL-CDR1, the VL-CDR2, and the VL-CDR3 are determined according to Kabat numbering scheme, Chothia numbering scheme, AbM numbering scheme, Contact numbering scheme, IMGT numbering scheme, or a combination thereof.
7. The antibody of claim 1 , wherein the antibody is human, humanized, or chimeric.
8. The antibody of claim 1 , wherein the antibody is a monoclonal antibody.
9. The antibody of claim 1 , wherein the antibody is a Fab, Fab′, F (ab′)2, Fv, scFv, (scFv)2, single chain antibody molecule, dual variable domain antibody, linear antibody, or V domain antibody.
10. The antibody of claim 1 , wherein the antibody comprises an Fc region.
11. The antibody of claim 1 , wherein:
(i) the antibody comprises a heavy chain constant region of a class selected from IgG, IgA, IgD, IgE, and IgM, or
(ii) the antibody comprises a heavy chain constant region of the class IgG and a subclass selected from IgG1, IgG2, IgG3, and IgG4.
Assignments (2)
LICENSE
Recorded Apr 8, 2024
From: ICONIC THERAPEUTICS, INC.
To: EXELIXIS, INC.
Reel/Frame 067035/0710 →
MERGER AND CHANGE OF NAME
Recorded Dec 28, 2022
From: ICONIC THERAPEUTICS, INC.; ICONIC MERGER SUB II, LLC
To: ICONIC THERAPEUTICS LLC
Reel/Frame 062228/0466 →
Continuity (8)
Continuation
16959652
Provisional Application
62713797
· Aug 2, 2018
Provisional Application
62713804
· Aug 2, 2018
Provisional Application
62646788
· Mar 22, 2018
Provisional Application
62613545
· Jan 4, 2018
Provisional Application
62613564
· Jan 4, 2018
References Cited (400)
US 4235871A
· Papahadjopoulos et al.
· 1980
[cited by applicant]
US 4501728A
· Geho et al.
· 1985
[cited by applicant]
US 4656127A
· Mundy
· 1987
[cited by applicant]
US 4676980A
· Segal et al.
· 1987
[cited by applicant]
US 4722848A
· Paoletti et al.
· 1988
[cited by applicant]
US 4816567A
· Cabilly et al.
· 1989
[cited by applicant]
US 4837028A
· Allen
· 1989
[cited by applicant]
US 4946778A
· Ladner et al.
· 1990
[cited by applicant]
US 5019369A
· Presant et al.
· 1991
[cited by applicant]
US 5132405A
· Huston et al.
· 1992
[cited by applicant]
US 5204253A
· Sanford et al.
· 1993
[cited by applicant]
US 5208020A
· Chari et al.
· 1993
[cited by applicant]
US 5217879A
· Huang et al.
· 1993
[cited by applicant]
US 5229275A
· Goroff
· 1993
[cited by applicant]
US 5279833A
· Rose
· 1994
[cited by applicant]
US 5545807A
· Surani et al.
· 1996
[cited by applicant]
US 5565332A
· Hoogenboom et al.
· 1996
[cited by applicant]
US 5567610A
· Borrebaeck et al.
· 1996
[cited by applicant]
US 5573905A
· Lemer et al.
· 1996
[cited by applicant]
US 5580859A
· Felgner et al.
· 1996
[cited by applicant]
US 5589369A
· Seidman et al.
· 1996
[cited by applicant]
US 5589466A
· Felgner et al.
· 1996
[cited by applicant]
US 5591669A
· Krimpenfort et al.
· 1997
[cited by applicant]
US 5622931A
· Edgington et al.
· 1997
[cited by applicant]
US 5662907A
· Kubo et al.
· 1997
[cited by applicant]
US 5814482A
· Dubensky, Jr. et al.
· 1998
[cited by applicant]
US 5843723A
· Dubensky, Jr. et al.
· 1998
[cited by applicant]
US 5849561A
· Falck-Pedersen
· 1998
[cited by applicant]
US 5849589A
· Tedder et al.
· 1998
[cited by applicant]
US 6015686A
· Dubensky, Jr. et al.
· 2000
[cited by applicant]
US 6037135A
· Kubo et al.
· 2000
[cited by applicant]
US 6083716A
· Nilson et al.
· 2000
[cited by applicant]
US 6090406A
· Popescu et al.
· 2000
[cited by applicant]
US 6194551B1
· Idusogie et al.
· 2001
[cited by applicant]
US 6296854B1
· Pushko et al.
· 2001
[cited by applicant]
US 6312946B1
· Yeh et al.
· 2001
[cited by applicant]
US 6365394B1
· Gao et al.
· 2002
[cited by applicant]
US 6413935B1
· Sette et al.
· 2002
[cited by applicant]
US 6610321B2
· Huang et al.
· 2003
[cited by applicant]
US 6737056B1
· Presta
· 2004
[cited by applicant]
US 6783939B2
· Olmsted et al.
· 2004
[cited by applicant]
US 7202351B1
· Sette et al.
· 2007
[cited by applicant]
US 7285265B2
· Vogels et al.
· 2007
[cited by applicant]
US 7291498B2
· Roy et al.
· 2007
[cited by applicant]
US 7332581B2
· Presta
· 2008
[cited by applicant]
US 7344872B2
· Gao et al.
· 2008
[cited by applicant]
US 7425328B2
· Wang
· 2008
[cited by examiner]
US 7435413B2
· Kirchhofer
· 2008
[cited by examiner]
US 7468181B2
· Vogels et al.
· 2008
[cited by applicant]
US 7494647B2
· Sato
· 2009
[cited by examiner]
US 7531180B2
· Polo et al.
· 2009
[cited by applicant]
US 7541038B2
· Kovacs et al.
· 2009
[cited by applicant]
US 7557200B2
· Wu et al.
· 2009
[cited by applicant]
US 7572453B2
· Polo et al.
· 2009
[cited by applicant]
US 7572628B2
· Dubensky, Jr. et al.
· 2009
[cited by applicant]
US 7605235B2
· Anderson et al.
· 2009
[cited by applicant]
US 7732129B1
· Zhang et al.
· 2010
[cited by applicant]
US 7744900B2
· Dubensky, Jr. et al.
· 2010
[cited by applicant]
US 7771979B2
· Polo et al.
· 2010
[cited by applicant]
US 7820440B2
· Vogels et al.
· 2010
[cited by applicant]
US 7838277B2
· Gao et al.
· 2010
[cited by applicant]
US 8052967B2
· Vogels et al.
· 2011
[cited by applicant]
US 8093021B2
· Hurtado et al.
· 2012
[cited by applicant]
US 8119336B2
· Sampath et al.
· 2012
[cited by applicant]
US 8158418B2
· Polo et al.
· 2012
[cited by applicant]
US 8216834B2
· Colloca et al.
· 2012
[cited by applicant]
US 8252574B2
· Mason et al.
· 2012
[cited by applicant]
US 8258082B2
· Ladner
· 2012
[cited by applicant]
US 8647864B2
· Polo et al.
· 2014
[cited by applicant]
US 8673319B2
· Colloca et al.
· 2014
[cited by applicant]
US 8691563B2
· Pushko et al.
· 2014
[cited by applicant]
US 8691730B2
· Vasquez et al.
· 2014
[cited by applicant]
US 8722044B2
· Almagro et al.
· 2014
[cited by applicant]
US 8951525B2
· Almagro et al.
· 2015
[cited by applicant]
US 8999333B2
· Almagro et al.
· 2015
[cited by applicant]
US 9017696B2
· Draper et al.
· 2015
[cited by applicant]
US 9024001B2
· Tang et al.
· 2015
[cited by applicant]
US 9101572B2
· Pushko et al.
· 2015
[cited by applicant]
US 9150641B2
· Kellenberger et al.
· 2015
[cited by applicant]
US 9150658B2
· Verploegen et al.
· 2015
[cited by applicant]
US 9168314B2
· Satijn
· 2015
[cited by examiner]
US 9192661B2
· Jain et al.
· 2015
[cited by applicant]
US 9217159B2
· Roy et al.
· 2015
[cited by applicant]
US 9234181B2
· Tang et al.
· 2016
[cited by applicant]
US 9249191B2
· Ueno et al.
· 2016
[cited by applicant]
US 9254265B2
· Geall et al.
· 2016
[cited by applicant]
US 9255126B2
· Polo et al.
· 2016
[cited by applicant]
US 9273288B2
· Mason et al.
· 2016
[cited by applicant]
US 9295646B2
· Brito et al.
· 2016
[cited by applicant]
US 9353353B2
· Nabel et al.
· 2016
[cited by applicant]
US 9453240B2
· Chamberlain et al.
· 2016
[cited by applicant]
US 9486519B2
· Sahin et al.
· 2016
[cited by applicant]
US 9487563B2
· Nabel et al.
· 2016
[cited by applicant]
US 9492565B2
· Satijn et al.
· 2016
[cited by applicant]
US 9512190B2
· Ueno et al.
· 2016
[cited by applicant]
US 9636410B2
· Brito et al.
· 2017
[cited by applicant]
US 9714297B2
· Verploegen et al.
· 2017
[cited by applicant]
US 9714435B2
· Dicks et al.
· 2017
[cited by applicant]
US 9790308B2
· Han et al.
· 2017
[cited by applicant]
US 9801897B2
· Geall et al.
· 2017
[cited by applicant]
US 20020137081A1
· Bandman
· 2002
[cited by applicant]
US 20030072767A1
· Gaiger et al.
· 2003
[cited by applicant]
US 20030157108A1
· Presta
· 2003
[cited by applicant]
US 20040115625A1
· Ebner
· 2004
[cited by applicant]
US 20050123555A1
· Olmsted et al.
· 2005
[cited by applicant]
US 20050196754A1
· Drmanac et al.
· 2005
[cited by applicant]
US 20060104944A1
· Mousa
· 2006
[cited by applicant]
US 20060198854A1
· Pushko
· 2006
[cited by applicant]
US 20070031442A1
· Sewell
· 2007
[cited by applicant]
US 20070224201A1
· Wu et al.
· 2007
[cited by applicant]
US 20080050393A1
· Tang et al.
· 2008
[cited by applicant]
US 20090253184A1
· Clarke et al.
· 2009
[cited by applicant]
US 20100286070A1
· Verheyden et al.
· 2010
[cited by applicant]
US 20130171241A1
· Geall
· 2013
[cited by applicant]
US 20130189351A1
· Geall
· 2013
[cited by applicant]
US 20130202684A1
· Geall et al.
· 2013
[cited by applicant]
US 20140141070A1
· Geall et al.
· 2014
[cited by applicant]
US 20140248314A1
· Swanson et al.
· 2014
[cited by applicant]
US 20140255472A1
· Geall et al.
· 2014
[cited by applicant]
US 20140271829A1
· Lilja et al.
· 2014
[cited by applicant]
US 20150140068A1
· Barnett et al.
· 2015
[cited by applicant]
US 20150307897A1
· Soden et al.
· 2015
[cited by applicant]
US 20160289674A1
· Bancel et al.
· 2016
[cited by applicant]
US 20170136130A1
· Satijn et al.
· 2017
[cited by applicant]
US 20180044431A1
· Verploegen et al.
· 2018
[cited by applicant]
US 20220257789A1
· Theunissen et al.
· 2022
[cited by applicant]
CA 2705787A1
· 2009
[cited by applicant]
CN 103119065A
· 2013
[cited by applicant]
CN 103443127A
· 2013
[cited by applicant]
CN 112203695A
· 2021
[cited by applicant]
CN 116322787A
· 2023
[cited by applicant]
EP 0453082A1
· 1991
[cited by applicant]
EP 1069185A1
· 2001
[cited by applicant]
EP 2044947A1
· 2009
[cited by applicant]
EP 2590670A2
· 2013
[cited by applicant]
EP 2590676A2
· 2013
[cited by applicant]
EP 3115061A1
· 2017
[cited by applicant]
FR 2650840A1
· 1991
[cited by applicant]
JP 2007534295A
· 2007
[cited by applicant]
JP 2009514895A
· 2009
[cited by applicant]
JP 2011504724A
· 2011
[cited by applicant]
JP 2014509856A
· 2014
[cited by applicant]
JP 2014209917A
· 2014
[cited by applicant]
JP 2017533886A
· 2017
[cited by applicant]
JP 2021501776A
· 2021
[cited by applicant]
KR 1020140019375A
· 2014
[cited by applicant]
WO WO1991002087A1
· 1991
[cited by applicant]
WO WO1991006309A1
· 1991
[cited by applicant]
WO WO1992015712A1
· 1992
[cited by applicant]
WO WO1993024640A2
· 1993
[cited by applicant]
WO WO9405328A1
· 1994
[cited by examiner]
WO WO1994005328A1
· 1994
[cited by applicant]
WO WO1995013392A1
· 1995
[cited by applicant]
WO WO1996013597A2
· 1996
[cited by applicant]
WO WO1996018372A2
· 1996
[cited by applicant]
WO WO1999051642A1
· 1999
[cited by applicant]
WO WO2001070984A2
· 2001
[cited by applicant]
WO WO2001073027A2
· 2001
[cited by applicant]
WO WO2003085107A1
· 2003
[cited by applicant]
WO WO2004023973A2
· 2004
[cited by applicant]
WO WO2004056312A2
· 2004
[cited by applicant]
WO WO2005016961A1
· 2005
[cited by applicant]
WO WO2007024708A2
· 2007
[cited by applicant]
WO WO2007047749A1
· 2007
[cited by applicant]
WO WO2007056352A2
· 2007
[cited by applicant]
WO WO2008122811A2
· 2008
[cited by applicant]
WO WO2008145685A1
· 2008
[cited by applicant]
WO WO2009036379A2
· 2009
[cited by applicant]
WO WO2009079185A2
· 2009
[cited by applicant]
WO WO2009089004A1
· 2009
[cited by applicant]
WO WO2010105256A1
· 2010
[cited by applicant]
WO WO2011128704A1
· 2011
[cited by applicant]
WO WO2011157741A2
· 2011
[cited by applicant]
WO WO2012006359A1
· 2012
[cited by applicant]
WO WO2012006377A2
· 2012
[cited by applicant]
WO WO2012009568A2
· 2012
[cited by applicant]
WO WO2012125559A1
· 2012
[cited by applicant]
WO WO2012172058A1
· 2012
[cited by applicant]
WO WO2012172277A1
· 2012
[cited by applicant]
WO WO2013006837A1
· 2013
[cited by applicant]
WO WO2014179363A1
· 2014
[cited by applicant]
WO WO2016041082A1
· 2016
[cited by applicant]
WO WO2016124670A1
· 2016
[cited by applicant]
WO WO2017042352A1
· 2017
[cited by applicant]
WO WO2017106638A1
· 2017
[cited by applicant]
WO WO2018195357A1
· 2018
[cited by applicant]
WO WO2019089973A1
· 2019
[cited by applicant]
WO WO2019102435A1
· 2019
[cited by applicant]
WO WO2019183253A1
· 2019
[cited by applicant]
WO WO2021003399A1
· 2021
[cited by applicant]
WO WO2022002940A1
· 2022
[cited by applicant]
Aalberse et al., IgG4 breaking the rules, Immunology, 2002, 105:9-19.
[cited by applicant]
Aarnoudse, et al., TCR Reconstitution in Jurkat Reporter cells facilitates the identification of novel tumor antigens Dy CDNA expression cloning, Int. J. Cancer, 99, pp. 7-13, (2002).
[cited by applicant]
Abdulkadir et al. “Tissue factor expression and angiogenesis in human prostate carcinoma,” Human Pathology, 2000, 31(4):443-447.
[cited by applicant]
Abelin et al., Complementary IMAC enrichment methods for HLA-associated phosphopeptide identification by mass spectrometry. Nat Protec. Sep. 2015; 10(9):1308-1318. doi: 10.1038/nprol.2015.086. Epub Aug. 6, 2015.
[cited by applicant]
Alexander et al., Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides, Immunity, vol. 1, Issue 9, pp. 751-761, Dec. 1994.
[cited by applicant]
Anders et al., HTSeq—a Python framework to work with high-throughput sequencing data. Bioinforma. Oxf. Engl. 31, 166-169 (2015), hllps://doi.org/10.1093/bioinformatics/btu638.
[cited by applicant]
Andreatta et al., Accurate pan-specific prediction of peptide-MHC class II binding affinity with improved binding core identification. Immunogenetics 67(11-12) 641-650, Nov. 2015.
[cited by applicant]
Andreatta et al., Gapped sequence alignment using artificial neural networks: application to the MHC class I system. Bioinforma. Oxf. Engl. (2015). doi:10.1093/bioinformatics/blv639.
[cited by applicant]
Arbabi Ghahroudi, Selection and identification of single domain antibody fragments from camel heavy-chain antibodies, FEBS Letters 414 (1997) 521-526.
[cited by applicant]
Armour et al., Differential binding to human FcgRlla and FcgRllb receptors by human lgG wildtype and mutant antibodies, Molecular Immunology, vol. 40, Issue 9, Dec. 2003, pp. 585-593, <hllps://doi.org/10.1016/j.molimm.2…
[cited by applicant]
Banu et al., “Building and Optimizing a Virus-specific T Cell Receptor Library for Targeted Immunotherapy in Viral Infections.” Scientific Reports 4:4166, 2014.
[cited by applicant]
Barbas et al., In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity, Proc. Nat. Acad. Sci. U.S.A., 1994, 91:3809-3813.
[cited by applicant]
Barnstable et al., Production of monoclonal antibodies to group A ery l hrocytes, HLA and other human cell surface antigens—new tools for genetic analysis. Cell. May 1978; 14(1):9-20.
[cited by applicant]
Bassani-Sternberg et al., Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation. Mol Cell Proteomics. Mar. 2015; 14(3):658-673. …
[cited by applicant]
Behrens et al., Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrates improved Homogeneity and other Pharmacological Properties over Conventional Heterogeneous ADCs, Mol Pharmaceuti…
[cited by applicant]
Beloncle et al., “Recruilability and effect of PEEP in SARS-Cov-2-associaled acute respiratory distress syndrome”, Ann. Intensive Care (2020) 10:55.
[cited by applicant]
Binz et al., Engineering novel binding proteins from nonimmunoglobulin domains, Nat. Biotechnol., 2005 23:1257-1268.
[cited by applicant]
Bodini et al. The hidden genomic landscape of acute myeloid leukemia: subclonal structure revealed by undetected mutations. Blood 125, 600-605 (2015).
[cited by applicant]
Boegel et al. HLA typing from RNA-Seq sequence reads, Genome Med. 4, 102 (2012).
[cited by applicant]
Boisvert et al. A Quantitative Spatial Proteomics Analysis of Proteome Turnover in Human Cells. Mol. Cell. Proteomics 11, M111.011429-1 (2012).
[cited by applicant]
Boshart, et al., A very strong enhancer is localed upstream of an immediate early gene of human cytomegalovirus, Cell, 41:521-530 (1985), https://doi.org/10.1016/S0092-8674(85)80025-8.
[cited by applicant]
Breij et al. “An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors,” Cancer Research, 2014, 74(4):1214-1226.
[cited by applicant]
Brennan et al., Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 ragmenls, Science, 1985, vol. 229, Issue 4708, pp. 81-83, DOI: 10.1126/science.3925553.
[cited by applicant]
Bromberg et al., Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation, Proc. Natl. Acad. Sci.US A., vol. 92, pp. 8205-8209, Aug. 1995.
[cited by applicant]
Brown et al., “Tolerance of single, but not multiple, amino acid replacements in antibody VH CDR 2: a means of minimizing B cell wastage from somatic hypermutation?”, J. Immuno. May 1996, 3285-91. (Year: 1996).
[cited by applicant]
Bruggemann et al., Designer mice: the production of human antibody repertoires in transgenic animals, Year in Immuno., 1993, 7:33.
[cited by applicant]
Calis et al. Properties of MHC Class I Presented Peptides That Enhance Immunogenicity. PLoS Comput. Biol. 9, e1003266 (2013).
[cited by applicant]
Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543-550 (2014).
[cited by applicant]
Carithers et al. A Novel Approach to High-Quality Postmortem Tissue Procurement: The GTEx Project. Biopreservation Biobanking 13, 311-319 (2015).
[cited by applicant]
Carlring et al., A Novel Redox Method for rapid Production of Functional Bi-Specific Antibodies for Use in Early Pilot Studies, PloS ONE 6(7): e22533, doi:10.1371/journal.pone.0022533.
[cited by applicant]
Carneiro-Lobo et al. “Ixolaris, a tissue factor inhibitor, blocks primary tumor growth and angiogenesis in a glioblastoma model,” J Thromb Haemost, 2009, 7(11):1855-1864.
[cited by applicant]
Carneiro-Lobo et al., lxolaris, a tissue factor inhibitor, blocks primary tumor growth and angiogenesis in a glioblastoma model, Journal of Thrombosis and Haemostasis, 2009, 7:1855-1864.
[cited by applicant]
Carreno et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma heoantigen-specific T cells. Science 348, 803-808 (2015).
[cited by applicant]
Carter et al., Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, pp. 413-421 (2012).
[cited by applicant]
Chahal, et al., Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose, PNAS, 2016 E4133-4142, www.pnas.org/cgi/doi/10.1073/pna…
[cited by applicant]
Chari et al., Immunoconjugates Containing Novel Maytansinoids: Promising Anticancer Drugs, Cancer Research 52, 127-131, Jan. 1, 1992.
[cited by applicant]
Chen et al. “Immunolocalisation of tissue factor in esophageal cancer is correlated with intratumoral angiogenesis and prognosis of the patient,” Acta Histochemica, 2010, 112(3):233-239.
[cited by applicant]
Chen et al., Tissue factor expression in rheumatoid synovium a potential role in pannus invasion of rheumatoid arthritis, Acta Hislochemica, 115 (2013), 692-697.
[cited by applicant]
Chen et al., Tissue factor expression in rheumatoid synovium a potential role in pannus invasion of rheumatoid arthritis, Acta Histochem., 2010, 3:233-239, <https://doi.org/10.1016/j.acthis.2013.02.005>.
[cited by applicant]
Chowdhury, Methods Mol. Biol., 2008, 207:179-196.
[cited by applicant]
Christensen et al., Urokinase-type plasminogen activator receptor (mPAR), tissue factor (TF) and epidermal growlh factor receptor (EGFR) tumor expression patterns and prognostic value in oral cancer, BMC Cancer, 2017, 1…
[cited by applicant]
Cibulskis et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213-219 (2013).
[cited by applicant]
Cieslik et al. The use of exome capture RNA-seq for highly degraded RNA with application to clinical cancer sequencing. Genome Res. 25, 1372-1381 (2015).
[cited by applicant]
Cocco et al., Expression of Tissue factor in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix: Implications for immunotherapy with hI-con1, a factor Vll-lgGFc chimeric protein targeting tissue factor, BM…
[cited by applicant]
Coloma et al., Design and production of novel tentravalent bispecific antibodies, Nature Biotechnol., 1997, 15:159-163.
[cited by applicant]
Cooper et al., Rescue of splicing-mediated intron loss maximizes expression in lentiviral vectors containing the human ubiquitin C promoter, Nucl. Acids Res. (2015) 43 (1): 682-690.
[cited by applicant]
Cornet et al., (2006) Optimal organization of a polypeptide-based candidate cancer vaccine composed of cryptic tumor peptides with enhanced immunogenicity. Vaccine 24, 2102-2109.
[cited by applicant]
Cox et al., “Immunoassay Methods,” in Assay Guidance Manual [Internet], Updated Dec. 24, 2014 (Cox et al., Immunoassay Methods, in Assay Guidance Manual [Internet], Updated Dec. 24, 2014 (www.ncbi.nlm.nih.gov/books/NBK9…
[cited by applicant]
Del Val, Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein, vol. 66, Issue 6, P1145-1153, Sep. 20, 1991, DOl:https://doi.org/10.10…
[cited by applicant]
Demoulins et al., Polyethylenimine-based polyplex delivery of self-replicating RNA vaccines, Nanomedicine: Nanotechnology, Biology and Medicine, vol. 12, Issue 3, Apr. 2016, pp. 711-722.
[cited by applicant]
Depla et al., Rational design of a multiepitope vaccine encoding T-lymphocyte epitopes for treatment of chronic hepatitis B virus infections. Journal of Virology 82, 435-450 (2008).
[cited by applicant]
Desrichard, et al., Cancer Neoantigens and Applications for Immunotherapy. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. (2015). doi:10.1158/1078-0432.CCR-14-3175.
[cited by applicant]
Duan, F. et al. Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer Immunogenicity. J. Exp. Med. 211, 2231-2248 (2014).
[cited by applicant]
Dupuis, et al., Dendritic Cells Internalize Vaccine Adjuvant after Intramuscular Injection, Cellular Immunology, vol. 186, Issue 1, May 25, 1998, pp. 18-27, https://doi.org/10.1006/cimm.1998.1283.
[cited by applicant]
Edwards et al., 2003, “The remarkable flexibility of the human antibody repertoire; isolation of over one thousand different antibodies to a single protein, BLyS,” J. Mol. Biol., 334(1):103-118.
[cited by applicant]
Eggers, et al., The Cleavage Preference of the Proteasome Governs the Yield of Antigenic Peptides, Journal of Experimental Medicine, vol. 182 Dec. 1995 1865-1870.
[cited by applicant]
Eng et al., A deeper look into Comet—implementation and features. J. Am Soc Mass Spectrom. Nov. 2015;26 (11):1865-74. doi: 10.1007/s13361-015-1179-x. Epub Jun. 27, 2015.
[cited by applicant]
Eng et al., Comet: an open-source MS/MS sequence database search tool. Proteomics. Jan. 2013;13(1):22-4. doi:10.1002/pmic.201200439. Epub Dec. 4, 2012.
[cited by applicant]
Extended European Search Report for Application No. 20835557.8, received on Jul. 4, 2023, 10 pages.
[cited by applicant]
Fang, et al. Stable antibody expression at therapeutic levels using the 2A peptide. Nat Biotechnol 23, 584-590 (2005).
[cited by applicant]
Farina et al., Replication-Defective Vector Based on a Chimpanzee Adenovirus, Journal of Virology, Dec. 2001, p. 11603-11613.
[cited by applicant]
Feck et al., “Protection of hDAF-Transgenic Porcine Endothelial Cells against Activation by Human Complement: Role of Membrane Attack Complex Introduction X,” Xenotransplantation, vol. 9, Mar. 2002, pp. 97-105.
[cited by applicant]
Felgner, Lipofaction A highly efficient, lipid-mediated DNA-transfaction procedure, Proc. Nall. Acad. Sci., vol. 84, p. 7413-7417, Nov. 1987.
[cited by applicant]
Finco et al., Comparison of competitive ligand-binding assay and bioassay formats for the measurement of eutralizing antibodies to protein therapeutics, J. Pharm. Biomed. Anal., 2011, vol. 54, Issue 2, Jan. 2011, pp. 35…
[cited by applicant]
Fisher et al., Biochem. J., 299:49 (Apr. 1, 1994).
[cited by applicant]
Fleeton et al., Self-Replicative RNA Vaccines Elicit Protection against Influenze A Virus, Respiratory Syncytial Virus, nd a Tickbome Encephalitis Virus, Journal of Infectious Diseases 183:1395-1398 2001.
[cited by applicant]
Frampton et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat. Biotechnol. 31, 1023-1031 (2013).
[cited by applicant]
Frolov et al., Cis-acting RNA elements at the 5′ end of Sindbis virus genome RNA regulate minus- and plus-strand RNA synthesis. RNA. Nov. 2001; 7(11):1638-1651.
[cited by applicant]
Furney et al. SF3B1 mutations are associated with alternative splicing in uveal melanoma. Cancer Discov. (2013). doi:10.1158/2159/8290.CD-13-0330.
[cited by applicant]
Gabrilovich et al., IL-12 and mutant P53 peptide-pulsed dendritic cells for the specific immunotherapy of cancer., J. Immunother Emphasis Tumor Immunol. 1996 (6):414-418.
[cited by applicant]
Gaudrealut et al.,“Preclinical Pharmacology and Safety of ESBA1008, a Single-Chain Antibody Fragment, Investigated as Potential Treatment for Age Related Macular Degeneration,” ARVO Annual Meeting Abstract, Mar. 2012, I…
[cited by applicant]
Geall, et al., Nonviral delivery of self-amplifying RNA vaccines, PNAS, 14604-14609, Sep. 4, 2012, vol. 109, No. 36, www.pnas.org/cgi/doi/10.1073/pnas.1209367109.
[cited by applicant]
Goding, Monoclonal Antibodies: Principles and Practice 3rd ed. (1986) Academic Press, San Diego, CA.
[cited by applicant]
Goel et al., 2004, “Plasticity within the antigen-combining site may manifest as molecular mimicry in the humoral immune response,” J. Immunol., 173(12):7358-7367.
[cited by applicant]
Goloman et al., HLA-DR monoclonal antibodies inhibit the proliferation of normal and chronic granulocytic leukemia myeloid progenitor cells. Br. J. Haemalol. Nov. 1982;52(3):411-420.
[cited by applicant]
Graaf et al., Curr Pharm Des, 2002, 8:1391-1403.
[cited by applicant]
Gros et al., Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients, Nat Med. (2016) 22 (4):433-438.
[cited by applicant]
Gruber et al., Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in
[cited by applicant]
Guan et al. “Tissue factor expression and angiogenesis in human glioma,” Clinical Biochemistry, 2002, 35(4):321-325.
[cited by applicant]
Gubin, et al. “Tumor neoantigens: building a framework for personalized cancer immunotherapy,” J. Clin. Invest. 125, 3413-3421 (2015).
[cited by applicant]
Hawkins et al., Selection of phage antibodies by binding affinity: Mimicking affinity maturation, Journal of Molecular Biology, vol. 226, Issue 3, 1992, pp. 889-896. https://doi.org/10.1016/0022-2836(92)90639-2.
[cited by applicant]
Hofer et al., An engineered selenocysteine defines a unique class of antibody derivatives, Proc. Nall. Acad. Sci. USA, 2008, 105:12451-12456.
[cited by applicant]
Hofer et al., Molecularly defined antibody conjugation through a selenocysteine interface, Biochemistry, 2009, 48 (50):12047-12057.
[cited by applicant]
Holliger et al., “Diabodies” Small bivalent and bispecific antibody fragments, Proc. Nall. Acad. Sci. USA, 1993, 90:6444-6448.
[cited by applicant]
Holy et al., Tissue Factor in Cardiovascular Disease: Pathophysiology and Pharmacological Intervention, Adv Pharmacol, 2010, 59:259-592, <htlps://doi.org/10.1016/S1054-3589(10)59009-4>.
[cited by applicant]
Hong et al., 2012, Immuno-PET of Tissue Factor in Pancreatic Cancer, J. Nucl. Med., 53(11):1748-1754.
[cited by applicant]
Hoogenboom et al., By-passing immunisation: Human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro, J. Mol. Biol., 1991, 227:381-388. <htlps://doi.org/10.1016/0022-2836(92)90894-P>.
[cited by applicant]
Hu et al., Immunization Delivered by Lentiviral Vectors for Cancer and Infectious Diseases, lmmunol Rev. (2011) 239 (1): 45-61, https://doi.org/10.1111/j.1600-065X.2010.00967.x.
[cited by applicant]
Huang et al. “The mechanism of an inhibitory antibody on TF-initiated blood coagulation revealed by the crystal structures of human tissue factor, Fab 5G9 and TF.G9 complex,” Journal of molecular biology, 1998, 275(5):8…
[cited by applicant]
Huang, et al., The immunodominant major histocompalibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product, Proc. Nall. Acad. Sci., vol. 93, pp. 9730-9735, S…
[cited by applicant]
Hunt et al., Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 1992. 255: 1261-1263.
[cited by applicant]
Idusogie et al., Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human lgG1 Fe, J. Immunol., 2000, 164:4178-4184.
[cited by applicant]
International Searching Authority, International Search Report and Written Opinion for International Patent Application No. PCT/US2019/012427 (Pub No. WO 2019136309) mailed May 17, 2019 (14 pages).
[cited by applicant]
International Searching Authority, International Search Report and Written Opinion for International Patent Application No. PCT/US2020/040711 (Pub No. WO 2021003399) mailed Dec. 15, 2020 (17 pages).
[cited by applicant]
International Searching Authority, International Search Report and Written Opinion for International Patent Application No. PCT/US2021/041191 (Pub No. WO 2022011323) mailed Dec. 2, 2021 (17 pages).
[cited by applicant]
Ishioka et al., Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes. J. Immunol 162, 3915-3925 (1999).
[cited by applicant]
Jackson et al., In vitro antibody maturation. Improvement of a high affinity, neutralizing antibody against IL-1 beta., J. Immunol., 1995, 154:3310-3319.
[cited by applicant]
Jakobovits et al., Analysis of homozygous mutant chimeric mice deletion of the immunoglobulin heavy-chain joining region blocks B-cell development and antibody production, Proc. Nall. Acad. Sci. U.S.A., 1993, 90:2551.
[cited by applicant]
Jakobovits et al., Germ-line transmission and expression of a human-derived yeast artificial chromosome, Nature, 1993, 362:255-258.
[cited by applicant]
James et al., Tetramer-guided epitope mapping reveals broad, individualized repertoires of tetanus toxin-specific CD4+ T cells and suggests HLA-based differences in epitope recognition, International Immunology, vol. 19…
[cited by applicant]
Janetzki et al., Guidelines for the automated evaluation of Elispot assays. Nat Protec 10, 1098-1115 (2015).
[cited by applicant]
Janeway, Jr. et al. Immunobiology—The Immune System in Health and Disease, Third Edition, 1997, Part II—The Recognition of Antigen and Part Ill—Structure of the Antibody Molecule and Immunoglobin Genes, 14 pages.
[cited by applicant]
Jayaraman Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo, Angew. Chem Inl. 2012, 51, 8529-8533.
[cited by applicant]
Jensen et al. “Improved Methods for Prediting Peptide Binding Affinity to MHC Class II Molecules.” Immunology, 2018, doi:10.1111/imm.12889.
[cited by applicant]
Johanning et al., A sindbis virus mRNA polynucleotide vector achieves prolonged and high level heterologous gene In vivo, Nucleic Acids Research, 1995, vol. 23, No. 9, 1495-1501.
[cited by applicant]
Johnson et al., Molecular Determinants of Alphavirus Neurovirulence: Nucleotide and Deduced Protein Sequence Changes during Attenuation of Venezuelan Equine Encephalitis Virus. J. Gen Virol 67:1951-1960, 1986.
[cited by applicant]
Jones et al., Replacing the complementarity-determining regions in a human antibody with those from a mouse, Nature, 1986, 321:522-525.
[cited by applicant]
Jorgensen et al., NetMHCstab—predicting stability of peptide-MHC-I complexes; impacts for cytotoxic T lymphocyte Epitope discovery. Immunology 141, 18-26 (2014).
[cited by applicant]
Jose et al., A structural and functional perspective of alphavirus replication and assembly. Future Microbiol. Sep. 2009;4(7):837-856.
[cited by applicant]
Kabat et al., Unusual Distributions of Amino Acids in Complementarity-determining (Hypervariable) Segments of Heavy and Light Chains of Immunoglobulins and Their Possible Roles in Specificity of Antibody-combining Sites…
[cited by applicant]
Kall et al., Assigning [confidence measures] significance to peptides identified by tandem mass spectrometry. Journal of Proteome Research, 7(1):29-34, Jan. 2008.
[cited by applicant]
Kall et al., Nonparametric estimation of posterior error probabilities associated with peptides identified by tandem mass spectrometry. Bioinformatics, 24(16):i42-i48, Aug. 2008.
[cited by applicant]
Kall et al., Semi-supervised learning for peptide identification from shotgun proteomics datasets. Nature Methods 4:923-925, Nov. 2007.
[cited by applicant]
Kanda et al., Comparison of cell lines for stable production of fucose-negative antibodies with enhanced ADCC, Biotechnol. Bioeng., 2006, 94:680-688.
[cited by applicant]
Kanyavuz et al., 2019, “Breaking the law: unconventional strategies for antibody diversification,” Nat. Rev. Immunol., 19(6):355-368.
[cited by applicant]
Kim et al. “A novel antibody-drug conjugate targeting SAIL for the treatment of hematologic malignancies,” Blood cancer journal, 2015, 5(5):1-8.
[cited by applicant]
Kinney et al., Nucleotide Sequence of the 26 S mRNA of the Virulent Trinidad Donkey Strain of Venezuelan Equine Encephalitis Virus and Deduced Sequence of the Encoded Structural Proteins. Virology 152 (2), 400-413. Jul.…
[cited by applicant]
Kipriyanov et al., “Generation and Production of Engineered Antibodies,” Mol Biotechnol. Jan. 2004; 26(1):39-60.
[cited by applicant]
Koizume et al. “Tissue Factor—Factor VII Complex as a Key Regulator of Ovarian Cancer Phenotypes,” Biomark Cancer, 2015, 7(S2):1-13.
[cited by applicant]
Kornher, et al., Mutation detection using nucleotide analogs that alter electrophoretic mobility, Nucleic Acids Research, vol. 17, Issue 19, Oct. 11, 1989, pp. 7779-7784, https://doi.org/10.1093/nar/17.19.7779.
[cited by applicant]
Kost, et al., The nucleotide sequence of the chich cytoplasmic B-actin gene, Nucleic Acids Research, vol. 11, Issue 23, Dec. 10, 1983, pp. 8287-8301, https://doi.org/10.1093/nar/11.23.8287.
[cited by applicant]
Kostelny et al., Formation of a bispecific antibody by the use of leucine zippers, J. Immunol., 1992, 148:1547-1553.
[cited by applicant]
Kovtun et al., Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance, Cancer Res., 2010, 70:2528-2537.
[cited by applicant]
Kozbor, A human hybrid myeloma for production of human monoclonal antibodies., J. Immunol., 1984, 133 (6) pp. 3001-3005.
[cited by applicant]
Kreiter et al., “Mutant MHC class II epitopes drive therapeutic immune responses to cancer,” Nature 520, 692-696, Apr. 2015.
[cited by applicant]
Kreiter Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals, J. Immunol 2008, 180:309-318, doi: 10.4049/jimmunol.180.1.309, http://www.jimmunol.org/contenl/180/1/309.
[cited by applicant]
Krieg et al., Functional messenger RNAs are produced by SP6 in vitro transcription of cloned cDNAs, Nucleic Acids Res. Sep. 25, 1984;12(18):7057-7070.
[cited by applicant]
Kuppuswamy et al., Single nucleotide primer extension to detect genetic diseases Experimental application to hemophilia B (factor IX) and cystic fibrosis genes, Proc. Natl. Acad. Sci. USA, vol. 88, pp. 1143-1174, Feb. 1…
[cited by applicant]
Lam et al. Nucleotide-resolution analysis of structural variants using BreakSeq and a breakpoint library. Nat. Biotechnol. 28, 47-55 (2010).
[cited by applicant]
Larsen et al. “Engineering of substrate selectivity for tissue factor.factor VIia complex signaling through protease-activated receptor 2,” The Journal of biological chemistry, 2010, 285(26):19959-19966.
[cited by applicant]
Larsen et al. An integrative approach to CTL epitope prediction: a combined algorithm integrating MHC class I binding, TAP transport efficiency, and proteasomal cleavage predictions. Eur. J. Immunol. 35, 2295-2303 (2005…
[cited by applicant]
LeFranc et al., IMGT unique numbering for immunoglobulin and T cell receptor variable domains and lg superfamily V-like domains, Dev Comp Immunol, 2003, 27:55-77.
[cited by applicant]
Lescar et al., 1995, “Crystal structure of a cross-reaction complex between Fab F9.13.7 and guinea fowl lysozyme,” J. Biol. Chem., 270(30):18067-18076.
[cited by applicant]
Li et al., RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics, 12:323, Aug. 2011.
[cited by applicant]
Liao-Chan et al. “Quantitative assessment of antibody internalization with novel monoclonal antibodies against Alexa fluorophores, ” PLoS One, 2015, 10(4):1-15.
[cited by applicant]
Liepe et al., A large fraction of HLA class I ligands are proteasome-generated spliced peptides. Science, Oct. 21, 2016.
[cited by applicant]
Liu et al. Athlates: accurate typing of human leukocyte antigen through exome sequencing. Nucleic Acids Res. 41, e142 (2013).
[cited by applicant]
Liu et al., N-terminal Glutamate to Pyroglutamate Conversion in Vivo for Human lgG2 Antibodies, J. Biol. Chem., 2011, 286:11211-11217.
[cited by applicant]
Ljungberg et al., Self-replicating alphavirus RNA vaccines, Expert Rev. Vaccines 14(2), 177-194 (2015).
[cited by applicant]
Lloyd et al., 2009, “Modelling the human immune response: performance of a 1011 human antibody repertoire against a broad panel of therapeutically relevant antigens,” Protein Eng. Des. Sel., 22(3):159-168 (Epub 2008).
[cited by applicant]
Lo et al. “Tissue factor expression in the metaplasia-adenoma-carcinoma sequence of gastric cancer in a European population,” British Journal of Cancer, 2012, 107(7):1125-1130.
[cited by applicant]
Lu et al., Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions, Clin Cancer Res. (2014) 20(13):3401-3410.
[cited by applicant]
Lundegaard et al., State of the art and challenges in sequence based T-cell epitope prediction. lmmunome Res. 6 Suppl 2, S3 (2010).
[cited by applicant]
Lundstrom, Alphavirus-Based Vaccines, Viruses 2014, 6, 2392-2415, doi: 10.3390/v6062392.
[cited by applicant]
Lyons et al., Influence of human COB on antigen recognition by T-cell receptor-transduced cells. Cancer Res 66, 11455-11461 (2006).
[cited by applicant]
Maguire et al. SF3B1 mutations constitute a novel therapeutic target in breast cancer. J. Pathol. 235, 571-580 (2015).
[cited by applicant]
Mannino & Gould-Fogerite, BioTechniques 6(7): 682-691 (1988).
[cited by applicant]
Maretty et al., Bayesian transcriptome assembly. Genome Biol. 15, 501 (2014).
[cited by applicant]
Marks et al., By-passing immunization: Human antibodies from V-gene libraries displayed on phage, J. Mol. Biol., 1991, 222:581-597.
[cited by applicant]
Martinon et al., Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped Mrna, European Journal of Immunology vol. 23, Issue 7, Jul. 1993, https://doi.org/10.1002/eji.1830230749.
[cited by applicant]
Mayor et al. HLA Typing for the Next Generation. PloS One 10, e0127153 (2015).
[cited by applicant]
McGranahan et al., Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution, Cell 171, 1259-1271.e11, (2017).
[cited by applicant]
Merchant et al., An efficient route to human bispecific lgG, Nature Biotechnol., 1998, 16:677-681.
[cited by applicant]
Miller et al., Design, Construction, and In Vitro Analyses of Multivalent Antibodies, J. Immunol., 2003, 170:4854-4861.
[cited by applicant]
Milstein et al., (Milstein and Cuello), Hybrid hybridomas and their use in immunohistochemistry, Nature, 1983, 305:537-540.
[cited by applicant]
Mommen et al., Sampling From the Proteome to the Human Leukocyte Antigen-DR (HLA-DR) Ligandome Proceeds via High Specificity. Mol Cell Proteomics 15(4): 1412-1423, Apr. 2016.
[cited by applicant]
Morea et al., Antibody modeling: implications for engineering and design., Methods, 2000, 20:267-279.
[cited by applicant]
Mose et al., ABRA: improved coding indel detection via assembly-based realignment. Bioinforma. Oxf. Engl. 30, 2813-2815 (2014).
[cited by applicant]
Muyldermans et al., Recognition of antigens by single-domain antibody fragments: the superfluous luxury of paired domains, Trends in Biochem. Sci., 2001, 26:230-245.
[cited by applicant]
Nagai, et al. (2012). Aurora kinase A-specific T-cell receptor gene transfer redirects T lymphocytes to display effective antileukemia reactivity. Blood 119, 368-376.
[cited by applicant]
Ngo et al. “CNTO 859, a humanized anti-tissue factor monoclonal antibody, is a potent inhibitor of breast cancer metastasis and tumor growth in xenograft models,” International journal of cancer, 2007, 120(6):1261-1267.
[cited by applicant]
Nielsen et al., The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage. Immunogenetics 57, 33-41 (2005).
[cited by applicant]
Nielsen, et al., NN-align—An artificial neural network-based alignment algorithm for MHC class II peptide binding prediction. BMC Bioinformatics 10:296, Sep. 2009.
[cited by applicant]
Nielsen, et al., “Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method.,” BMC Bioinformatics 8:238, Jul. 2007.
[cited by applicant]
Nussbaum, et al., Cleavage motifs of the yeast 20S proteasome B subunits deduced from digests of enolase 1, Proc Natl. Acad. Sci. USA, vol. 95, pp. 12504-12509, Oct. 1998, Immunology.
[cited by applicant]
Nyren, et al., Solid Phase DNA Minisequencing by an Enzymatic Luminometric Inorganic Pyrophosphate Detection Assay, Analytical Biochemistry, vol. 208, Issue 1, Jan. 1993, pp. 171-175, https://doi.org/10.1006/bio.1993.10…
[cited by applicant]
Ouahabi et al., 1996, “Double long-chain amidine liposome-mediated self replicating RNA transfection,” FEBS Lett., 380(1-2):108-112.
[cited by applicant]
Panina-Bordignon et al., Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by Tcells, Eur. J. Immunol. 19, 2237-2242 (1989).
[cited by applicant]
Patry et al. “Tissue factor expression correlates with disease-specific survival in patients with node-negative muscle-invasive bladder cancer,” International journal of cancer, 2008, 122(7):1592-1597.
[cited by applicant]
Paul, Fundamental Immunology 7th ed., Ch. 5 (2013) Lippincott Williams & Wilkins, Philadelphia, PA.
[cited by applicant]
Pearson et al., MHC class I-associated peptides derive from selective regions of the human genome. The Journal of Clinical Investigation, 2016.
[cited by applicant]
Pertea et al. StringTie enables improved reconstruction of a transcriptome from RNA-seq reads. Nat. Biotechnol. 33, 290-295 (2015).
[cited by applicant]
Polo et al., Stable alphavirus packaging cell lines for Sindbis virus- and Semliki Forest virus-derived vectors, Proc. Natl. Acad. Sci. vol. 96, pp. 4598-4603, Apr. 1999.
[cited by applicant]
Presta, Antibody engineering, Curr. Op. Strucl. Biol., 1992, vol. 2, Issue 4, pp. 593-596.
[cited by applicant]